Archives: Press Releases
Modulus Discovery Announces Research Collaboration with Fujitsu on the Implementation and Optimization of ModBind™, A Novel Computational Technology for Drug Discovery
News -
08 August, 2022 -
Modulus Discovery, Inc., a computation-driven drug discovery company, announced today the signing of a research collaboration with Fujitsu Limited and the unveiling of its proprietary computational technology platform, ModBind™. The collaboration will accelerate the large-scale deployment of Modulus discovery tools across world-leading supercomputers, including the supercomputer “Fugaku”(*1), and AI Bridging Cloud Infrastructure (ABCI, *2). ModBind ...continuedModulus Discovery Closes $20.4M USD Series C
News -
01 March, 2022 -
Tokyo, Japan – Modulus Discovery, Inc., a preclinical-stage computation-driven drug discovery firm, announces the successful closing of its Series C funding round in the amount of 2.34B JPY (approximately $20.4M USD). Series C investors include Green Coinvest Investment Limited Partnership., SBI Group., Heights Capital Management, Inc., and existing shareholders including UTokyo Innovation Platform Co., Ltd., ...continuedNissan Chemical and Modulus Discovery Jointly Announce Signing of Strategic Drug Discovery Collaboration Agreement
News -
21 April, 2021 -
Nissan Chemical Corporation (Head Office: Chuo-ku, Tokyo Japan; President: Shinsuke Yagi, “Nissan Chemical”), and Modulus Discovery, Inc. (Head Office: Chiyoda-ku, Tokyo Japan; CEO: S. Roy Kimura, Ph.D., “Modulus”), an early stage global biopharmaceutical company, jointly announced today the signing of a strategic drug discovery collaboration agreement. Under this agreement, the companies will collaboratively accelerate the ...continuedModulus Discovery, Inc. to Present at the 39th Annual J.P. Morgan Healthcare Conference
News -
14 December, 2020 -
Modulus Discovery Inc. (“Modulus”), a pre-clinical stage technology-driven drug discovery company announced today that it was invited to present at the 39th Annual J.P. Morgan Healthcare Conference in January 2021. The J.P. Morgan Healthcare Conference, which attracts over 500 companies and 12,000 investors, is going virtual for 2021, and the webcast will be made available ...continuedModulus Discovery Announces Signing of a Collaboration Agreement with the University Of Tokyo to Pursue Drug Discovery for COVID-19 and Related Emerging Virus Infections
News -
02 October, 2020 -
Modulus Discovery, Inc., a preclinical-stage technology-driven drug discovery company announced today the initiation of a research collaboration with Professor Tsutomu Suzuki of Department of Chemistry and Biotechnology, Graduate School of Engineering, University of Tokyo to pursue drug discovery on a novel target for COVID-19 and related emerging virus infections. Emerging viruses are now becoming one ...continuedModulus Discovery Receives “Mizuho Innovation Award”
News -
28 July, 2020 -
We are pleased to announce that Modulus Discovery, Inc. has been awarded the Mizuho Innovation Award which recognizes the top innovative companies in Japan. We hope to work together with Mizuho Bank and capitalize on its broad industry ties to accelerate our search for much needed new medicines through our globally networked research model and ...continuedModulus Discovery Closes $25.5M USD Series B
News -
13 May, 2020 -
Tokyo, Japan – May 13, 2020 – Modulus Discovery, Inc., a preclinical-stage technology-driven drug discovery firm, announces the successful closing of its series B funding round in the amount of 2.71 B JPY (approximately $25.5M USD). Series B investors include SBI Investments Co., Ltd., Mizuho Capital Co., Ltd., JAFCO Co., Ltd., Keio Innovation Initiative, Inc., ...continuedModulus Discovery Announces Signing of Research Data Transfer Agreement with Astellas Pharma Inc.
News -
30 May, 2019 -
Modulus Discovery, Inc. (CEO: S. Roy Kimura, Ph.D., “Modulus”), an early stage global biopharmaceutical company, announced today the signing of research data transfer agreement on a specific drug target with Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”). Under the terms of the agreement, Modulus plans to design, evaluate and optimize ...continued